Trial Profile
Tolerability and Safety of Multiple Dose Regimens of TRX4 Anti-CD3 Monoclonal Antibody in Type 1 Diabetes Mellitus
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jul 2017
Price :
$35
*
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Tolerx
- 27 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Jul 2011 New trial record